Digestive Diseases and Sciences

, Volume 52, Issue 3, pp 732–736 | Cite as

Pegylated Interferon and Ribavirin Failures: Is Retreatment an Option?

  • Rekha Cheruvattath
  • Marianne J. Rosati
  • Manjushree Gautam
  • Hugo E. Vargas
  • Jorge Rakela
  • Vijayan Balan
Original Article

Abstract

Currently, there are limited therapeutic options available for chronic hepatitis C (HCV) patients who fail treatment with peginterferon α (PEG IFN) + ribavirin (RBV). An option is retreatment with a second course PEG-IFN + RBV. However, the virologic clearance with this option is unknown. Thus, we evaluated the outcome of our cohort of patients with chronic HCV who achieved a sustained viral response when retreated with PEG IFN plus RBV after having no response to an initial course of PEG IFN plus RBV. Nonresponse to treatment was defined as failure to achieve an early virologic response by week 12 or presence of detectable HCV RNA at week 24 or after completion of PEG-IFN + RBV therapy. Twenty patients (12 [60%] men; 8 [40%] women) were treated with PEG IFN α-2b plus RBV and PEG IFN α-2a plus RBV. The mean age of the patients was 50 years, 85% were white, 95% had genotype 1, and 35% had cirrhosis. Prior to the first course of PEG IFN plus RBV, 12 (60%) of 20 patients had no prior treatment for Hepatitis C. After the second course of PEG IFN plus RBV, 2 (10%) of 20 patients achieved a sustained virologic response. These results suggest marginal benefit of retreatment of patients with chronic HCV with another course of PEG IFN plus RBV after they have not responded to an initial course of PEG IFN plus RBV.

Keywords

Hepatitis C Chronic Interferon Peginterferon Retreatment Ribavirin 

References

  1. 1.
    Heathcote J, Main J (2005) Treatment of hepatitis C. J Viral Hepatitis 12:223–235CrossRefGoogle Scholar
  2. 2.
    Shiffman ML, Di Bisceglie AM, Lindsay KL et al (2004) Peginterferon alpha-2a and ribavirin in patients with chronic hepatitis C who have failed prior treatment. Gastroenterology 126:1015PubMedCrossRefGoogle Scholar
  3. 3.
    Brunt EM (2000) Grading and staging the histopathological lesions of chronic hepatitis: the Knodell histology activity index and beyond. Hepatology 31:241–246PubMedCrossRefGoogle Scholar
  4. 4.
    Cummings KJ, Lee SM, West ES et al (2001) Interferon and ribavirin vs interferon alone in the re-treatment of chronic hepatitis C previously nonresponsive to interferon: a meta-analysis of randomized trials. JAMA 285:193PubMedCrossRefGoogle Scholar
  5. 5.
    Kwo PY (2000) Treatment of chronic hepatitis C in nonresponders to interferon monotherapy. Curr Gastroenterol Rep 2:11–17PubMedGoogle Scholar
  6. 6.
    Egusa K. Kondo J (2003) Efficacy of interferon retreatment on interferon-resistant patients with chronic hepatitis C. Acta Medica Okayama 57:151–158PubMedGoogle Scholar
  7. 7.
    Fattovich G, Zagni I, Ribero ML et al (2004) A randomized trial of prolonged high dose of interferon plus ribavirin for hepatitis C patients, nonresponders to interferon alone. J Viral Hepatitis 11:543–551CrossRefGoogle Scholar
  8. 8.
    Jacobsen IM, Ahmed F, Russo MW, et al (2003) Pegylated interferon alfa-2b plus ribavirin in patients with chronic hepatitis C: a trial in non-responders to interferon monotherapy or combination therapy and in combination therapy relapsers: final results. Gastroenterology 124:A540Google Scholar
  9. 9.
    Shiffman ML (2004) Retreatment of patients who do not respond to initial therapy for chronic hepatitis C. Cleve Clin J Med 71(suppl 3):S13–16PubMedCrossRefGoogle Scholar
  10. 10.
    Castro FJ, Esteban JI, Juarez A et al (2002) Early detection of nonresponse to interferon plus ribavirin combination treatment of chronic hepatitis C. J Viral Hepatitis 9:202–207CrossRefGoogle Scholar
  11. 11.
    Gavier B, Martinez-Gonzalez MA, Riezu-Boj JI et al (1997) Viremia after one month of interferon therapy predicts treatment outcome in patients with chronic hepatitis C. Gastroenterology 113:1647–1653PubMedCrossRefGoogle Scholar
  12. 12.
    Ferenci P, Fried MW, Chaneac M (2003) A dynamic mode to predict sustained virological response to combination peginterferon alfa-2a and ribavirin therapy in patients with chronic hepatitis C. Hepatology 38(4 Suppl 1):A995Google Scholar
  13. 13.
    Strader DB, Wright T, Thomas DL, Seeff LB (2004) American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C. Hepatology 39:1147–1171PubMedCrossRefGoogle Scholar
  14. 14.
    Cornberg M, Hadem J, Herrmann E et al (2006) Treatment with daily consensus interferon (CIFN) plus ribavirin in non-responder patients with chronic hepatitis C: a randomized open-label pilot study. J Hepatol 44:291–301PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, Inc. 2006

Authors and Affiliations

  • Rekha Cheruvattath
    • 1
  • Marianne J. Rosati
    • 1
  • Manjushree Gautam
    • 1
  • Hugo E. Vargas
    • 1
  • Jorge Rakela
    • 1
  • Vijayan Balan
    • 1
    • 2
  1. 1.Transplant MedicineMayo ClinicScottsdaleUSA
  2. 2.Division of Gastroenterology and Hepatology, Transplant MedicineMayo ClinicScottsdaleUSA

Personalised recommendations